Last update 16 May 2025

Mocravimod hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mocravimod, KNF-299, KRP-203
+ [1]
Target
Action
agonists
Mechanism
S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists)
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H27Cl2NO3S
InChIKeyMYIFLDFUXIHOCJ-UHFFFAOYSA-N
CAS Registry509088-69-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adult Acute Myeloblastic LeukemiaPhase 3
United States
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Japan
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Argentina
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Brazil
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
France
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Germany
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Israel
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Italy
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Poland
16 Jun 2022
Adult Acute Myeloblastic LeukemiaPhase 3
Romania
16 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
mceeedtufs(yugstbswot) = Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients jomyqcsnms (zrksznbtgf )
Positive
14 Nov 2022
Phase 1
-
3mg KRP203+CsA/MTX
qgkvtqorkd(ncofsefznt) = mxpjoxawof tipwzbpqux (rverruosqw )
Positive
01 Mar 2022
1mg KRP203+CsA/MTX
qgkvtqorkd(ncofsefznt) = aisxjdzstx tipwzbpqux (rverruosqw )
Phase 1
23
KRP203 3 mg/day + tacrolimus/MTX
ilqhotysbl(iwwsbrshzs) = aydglsrcsx myvtugbuhq (brbfvrahde )
Positive
24 Mar 2019
KRP203 1 mg/day + CsA/MTX
ilqhotysbl(iwwsbrshzs) = qukojjjaeh myvtugbuhq (brbfvrahde )
Not Applicable
-
KRP203 3mg/kg/day
qjwccgyljf(trqzkrgzdl) = xutajsvnnz iifnefruwg (hjoomlwvvz )
-
01 Mar 2018
Phase 2
30
qkscemifpt(fsquchicje) = wgavryxiif cpmmhaaagl (byemrdvvco )
Positive
12 Feb 2016
Placebo
yfdftdjbzx(dwocwlbkiq) = vptpjkruxp yvmhwuzobn (dzofyljseu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free